2-(2-Oxo-5-phenylpiperidin-1-yl)butanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-(2-Oxo-5-phenylpiperidin-1-yl)butanamide
• 化学式: C₁₅H₂₀N₂O₂
• 分子量: 260.33
• InChiKey: UTTNZVOVSJFDKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  63.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders
  申请人：——

  公开号：US20040132717A1

  公开（公告）日：2004-07-08

  This invention relates to new 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives of formula (1) having anticonvulsant activity which are useful as therapeutic agents for the treatment or prevention of epilepsy and other neurological disorders. The invention also concerns processes for preparing these derivatives and novel intermediates used in the preparation of these derivatives. 1

  本发明涉及公式（1）的新的2-氧代哌啶基和2-氧代氮杂丙基脂肪酸衍生物，具有抗惊厥活性，可用作治疗或预防癫痫和其他神经系统疾病的治疗剂。本发明还涉及制备这些衍生物的方法以及用于制备这些衍生物的新型中间体。
• 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders
  申请人：Michel Philippe

  公开号：US20060258704A1

  公开（公告）日：2006-11-16

  This invention relates to new 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives of formula (1) having anticonvulsant activity which are useful as therapeutic agents for the treatment or prevention of epilepsy and other neurological disorders. The invention also concerns processes for preparing these derivatives and novel intermediates used in the preparation of these derivatives.

  本发明涉及具有抗惊厥活性的新的2-氧代哌啶基和2-氧代氮杂丙基脂肪酸衍生物，其化学式为（1），可用作治疗或预防癫痫和其他神经系统疾病的治疗剂。本发明还涉及制备这些衍生物的方法和用于制备这些衍生物的新型中间体。
• Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
  申请人：UCB S.A.

  公开号：EP1426768A2

  公开（公告）日：2004-06-09

  The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam SV2 proteins, including SV2A.

  本发明涉及鉴定 SV2 蛋白特性和功能的方法。本发明还包括鉴定调节 SV2 蛋白活性的化合物或制剂的方法。这些方法包括鉴定调节左乙拉西坦 SV2 蛋白（包括 SV2A）结合的化合物或制剂。
• LEVETIRACETAM FOR IMPROVING COGNITIVE FUNCTION
  申请人：The Johns Hopkins University

  公开号：EP3400934A1

  公开（公告）日：2018-11-14

  This invention relates to methods and compositions for treating central nervous system (CNS) disorders with cognitive impairment. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating central nervous system (CNS) disorders with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrphic lateral sclerosis and cancer-therapy-related cognitive impairment.

  本发明涉及治疗伴有认知障碍的中枢神经系统（CNS）疾病的方法和组合物。特别是，本发明涉及突触小泡糖蛋白 2A (SV2A)抑制剂单独或与丙戊酸钠联合用于治疗有需要或有风险的受试者（包括但不限于有年龄相关认知障碍或有年龄相关认知障碍风险的受试者）的伴有认知障碍的中枢神经系统 (CNS) 疾病、轻度认知功能障碍（MCI）、失忆性 MCI（aMCI）、年龄相关记忆障碍（AAMI）、年龄相关认知功能衰退（ARCD）、痴呆、阿尔茨海默病（AD）、前驱 AD、创伤后应激障碍（PTSD）、精神分裂症、肌萎缩侧索硬化症和癌症治疗相关认知功能障碍。
• BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION
  申请人：The Johns Hopkins University

  公开号：EP3827820A1

  公开（公告）日：2021-06-02

  This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism, compulsive behavior, and substance addiction.

  本发明涉及治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法和组合物。特别是，本发明涉及突触小泡糖蛋白 2A (SV2A)抑制剂单独或与丙戊酸钠联合用于治疗与中枢神经系统 (CNS) 疾病相关的认知功能损害，需要治疗或有治疗风险的受试者包括但不限于有年龄相关认知功能损害、轻度认知功能损害 (MCI) 或有此风险的受试者、老年痴呆症、阿尔茨海默病（AD）、前驱 AD、创伤后应激障碍（PTSD）、精神分裂症、双相情感障碍、肌萎缩性脊髓侧索硬化症、癌症治疗相关认知障碍、智力迟钝、帕金森病、自闭症、强迫行为和药物成瘾。